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Maternal antibody-mediated fetal red blood cell destruction 
secondary to non-D Rh system antibodies is a significant cause 
of hemolytic disease of the fetus and newborn. Here, we report 
a rare case of severe perinatal hemolytic disease associated 
with maternal antibody to the e antigen. In addition to severe 
anemia, the infant developed hyperbilirubinemia. Resolution 
of the infant’s anemia and hyperbilirubinemia occurred after 
treatment with phototherapy, intravenous immunoglobulin, and 
transfusion. Immunohematology 2021;37:72–77. DOI: 
10.21307/immunohematology-2021-011.
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Hemolytic disease of the fetus and newborn (HDFN) is 
an alloimmune condition in which shortened survival of the 
red blood cells (RBCs) of the fetus or the newborn is caused by 
maternal antibodies passing through the placenta and binding 
to the corresponding antigen on the fetal RBCs.
The pathogenesis of HDFN is based on a blood group 
incompatibility between the mother and fetus, where the fetal 
RBCs have antigens of paternal origin that are lacking on 
the mother’s RBCs. If the mother has an immune response 
to these antigens, the resulting immunoglobulin (Ig)G class 
antibody can cross the placenta and attach to and facilitate 
hemolysis of the antigen-positive fetal RBCs. An exception 
to this process is ABO-HDFN, in which the maternal IgG 
antibodies are preformed and do not depend on paternal origin 
for stimulation.
For this condition to occur, it is also necessary that 
the antigen encoded by the inherited paternal gene is fully 
expressed on the fetal RBCs and stimulates the formation of 
an IgG antibody. The passage of these antibodies through the 
placenta causes a diversity of symptoms in an antigen-positive 
fetus or newborn, ranging from mild anemia to death.1
Alloimmunization against D during pregnancy is the 
most frequent cause of severe HDFN, but antibodies to other 
specificities within the Rh and other blood group systems can 
also give rise to HDFN.
We report a case of HDFN in which solely anti-e was 
shown to cause severe symptoms.
Case Report
A white male neonate was born at 39.5 weeks’ gestation 
to a 39-year-old group A, D+ woman. She had a total of 
10 pregnancies: nine abortions and the current full-term 
pregnancy, which had progressed without obstetric compli-
cations. She reported a history of prior RBC transfusion.
The infant showing a cephalic presentation was born 
by vaginal delivery without fetal distress and had a normal 
and attached placenta, clear amniotic fluid, 9/9 APGAR, and 
a birth weight of 3100 g. The physical examination at birth 
revealed good general condition, moist skin, and mucous 
membranes without infiltrates; audible sounds in both lungs 
(respiratory rate 44 per minute without rales; normal 44 per 
minute); rhythmic heart sounds with good intensity and no 
murmurs (heart rate 136 beats per minutes; normal range 
120–160 beats per minutes); and a soft and predictable 
abdomen that was not painful on palpation. Complete blood 
count, reticulocyte count (CR), total bilirubin, and ABO and D 
typing were performed with the following results: hematocrit 
(Hct): 60 percent (reference range 42–60%); CR: 3 percent 
(reference range 2–6%); total bilirubin: 55 µmol/L (normal 
<103 µmol/L); and phenotype group A, D+.
At 8 hours after delivery, the baby maintained a good 
general condition but had slight jaundice, so it was decided to 
perform a direct antiglobulin test (DAT) and repeat the Hct, 
CR, and bilirubin. Phototherapy was also initiated. The results 
of the additional tests showed the following results: decrease 
in Hct from 60 to 38 percent, accompanied by increased 
reticulocytosis (217%), total bilirubin of 292 µmol/L, 
unconjugated bilirubin of 204 µmol/L, and a positive DAT.
This abrupt decrease in Hct accompanied by reticu-
locytosis, hyperbilirubinemia, and positive DAT raised a 
strong suspicion of HDFN due to an antibody directed at 
antigens other than ABO or D. Peripheral blood samples from 
both parents and the baby were sent to the Laboratory of 
Immunohematology at the National Institute of Hematology 
and Immunology (Havana, Cuba) for immunohematologic 
investigation.
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The treatment was initiated with intravenous immuno-
globulin (IVIG) at a dose of 500 mg/kg/day and phototherapy 
during the first and second day. Total bilirubin levels remained 
stable (between 254 and 300 mmol/L; unconjugated bilirubin 
levels were between 166 and 212 mmol/L), and CR decreased 
to 10 percent. Jaundice, however, remained in covered areas of 
the body, and Hct values decreased to 30 percent. Increasing 
the phototherapy to twice daily and the IVIG dose to 1 g/kg/
day caused a decrease in total bilirubin after 3 days. After 
transfusion of 62 mL RBC concentrate at a rate of 10 mL/kg, 
Hct levels rose to 53 percent. The newborn remained under 




ABO, Rh, and K1 typings of RBC samples from both 
parents and newborn were performed by standard tube 
testing with monoclonal reagents according to manufacturers’ 
instructions (Anti-A, Anti-B, Anti-A,B, and Anti-D; ior Hemo-
CIM SC, LABEX, Santiago de Cuba, Cuba; Anti-C, Anti-c, 
Anti-E, Anti-e, and Anti-K1; SPINREACT, SA, Girona, Spain).
The DAT was performed using polyspecific antihuman 
globulin (AHG) and monospecific anti-IgG and anti-C3d 
reagents (Anti-IgG/Anti-C3d, Anti-IgG, and Anti-C3d; 
Bio-Rad Medical Diagnostics, Cressier, Switzerland) after 
manually washing a sample of the infant’s RBCs three times.
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Table 1. Primers used for RH PCR-SSP
Exon Name of primers DNA sequence of primers (5 -́3´) Resulting specificity
2 D-2-201(sense) GCTTGGGCTTCC TCA CCT CG RHD/C
D-2-307(anti-sense) CAG TGT GAT GAC CAC CTT CCC AGA
3 D-3-383(sense) TGTCGGTGCTGATCT CAG TGG A RHD
D-3-451 (anti-sense) ACT GAT GAC CAT CCT CAG GTT GCC
4 D-4-527 (sense) ACA TGATGC ACA TCTACGTGTTCG C RHD
D-4-602 (anti-sense) CAG ACA AACTGG GTA TCG TTG CTG
5 D-5-676 (sense) ATGTTCTGGCCAAGTGTCAACTCT G RHD
D-5-787 (anti-sense) CTG CTC ACC TTG CTG ATC TTC CC
6 D-6-826 (sense) TTATGTGCA CAG TGCGGTGTT GG RHD
D-6-916 (anti-sense) CAG GTA CTTGGCTCC CCC GAC
7 D-7-967 (sense) GTT GTA ACC GAG TGCTGGGGATTC RHD
D-7-1048 (anti-sense) TGCCGG CTC CGACGG TAT C
9 D-9-1168 (sense) TAT GCATTT AAA CAG GTTTGCTCCTAA ATC RHD
D-9-1193 (anti-sense) AGA AAA CTTGGT CAT CAA AAT ATT TAG CCT
10 D-10-1255 (sense) TCC TCA TTTGGCTGTTGG ATT TTA AG RHD
D-10-1358 (anti-sense) CAG TGCCTGCGCGAA CAT TG
C/c C-1-(-24) (sense) GAT GCC TGGTGCTGGTGGAAC RHC/c (cyt 48)
C-1-48 (anti-sense) GCTGCTTCCAGT GTA GGG CG
c C-2-201(sense) GGC TTG GGCTTC CTC ACC TCA RHc/c (cyt 48)
C-2-307 (anti-sense) AGT GTG ATG ACC ACCTTCCCA GG
E/E E-5-676 (sense) GAT GTTCTG GCC AAGTGT CAA CTC TC RHE
5 D-5-676 (sense) ATGTTCTGGCCAAGTGTCAACTCT G RHe
e/e E-5-787 (anti-sense) CTG CTC ACC ATGCTG ATC TTC CT
C/C C-IN2-s 5ʹ-GCTCTGTTGCCCAGTCTGAAGTG-3ʹ
C-IN2-as 5ʹ-CCACTGGGAAGTGACAAAGGGC-3ʹ
For all primers, the respective exons, their specificity for RHD and RHCE alleles, and their position from the 3´ end on the RHD and RHCE coding sequences 
are given.
PCR-SSP = polymerase chain reaction using sequence-specific primers.
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A postpartum maternal serum sample was used for 
antibody detection, identification, and titration studies. 
The antibody specificity was determined using an antibody 
identification RBC panel; this RBC panel was obtained from 
voluntary blood donors and prepared in the immunohematology 
laboratory of our institution (Institute of Hematology and 
Immunology, Havana, Cuba). The serum was also tested 
against papain-treated RBCs (Sigma-Aldrich, St. Louis, MO). 
Titrations were performed using the tube method by indirect 
antiglobulin test (IAT) against untreated RBCs and papain-
treated RBCs. All procedures were performed according to the 
protocols in the AABB Technical Manual.2
Molecular Study
The molecular study was performed following the protocol 
of Gassner et al.3 The DNA was extracted from EDTA- 
anticoagulated whole blood obtained from both parents 
and the newborn, using the QIAcube equipment (QIAGEN, 
Hilden, Germany). The RHD/RHCE testing was performed 
by polymerase chain reaction (PCR) using sequence-specific 
primers (PCR-SSP; Eurofins Genomics, Ebersberg, Germany) 
(Table 1).
In each PCR, human growth hormone was used as a 
positive amplification control. The detection concentration 
of the primers was 0.2 µmol/L, with the exception of PCRs 
7 and 11, in which 0.1 µmol/L was used, respectively. The 
concentration of the control primers was 0.05 µmol/L 
(0.08 µmol/L in PCRs 9, 10, and 12). The amplification reaction 
was performed with a final volume of 25 µL, containing 
Colorless Gotaq Flexi Buffer 5× (Promega, Madison, WI) and 
a DNA concentration of 50 pmol/L. MgCl2 concentrations were 
different between the different mixtures: 0.9 mmol/L (PCR 10), 
1.1 mmol/L (PCR 5), 1.2 mmol/L (PCRs 1 and 4), 1.35 mmol/L 
(PCR 12), and 1.5 mmol/L (PCRs 2, 3, 6, 9, and 11). To facilitate 
the study, all mixtures were subjected to the same amplification 
conditions in the thermal cycler (Quanta BiotechQ Cycler II). 
The conditions were an initial denaturation step of 120 seconds 
at 94°C, 10 incubation cycles for 10 seconds at 94°C and 60 
seconds at 65°C; and 20 incubation cycles for 30 seconds at 
94°C, 60 seconds at 61°C, and 30 seconds at 72°C.
The amplification was read by capillary electrophoresis 
in QIAxcel Advance equipment (QIAGEN) with the use 
of the QIAxcel DNA Fast Analysis Kit (QIAGEN). The 
interpretation of the results was made through the presence 
of the amplification of the specific band and with the use of 
Helmberg-Score (Olerup) software.
Results
RBC typings on the three samples were as follows: 
mother: group A, D+C–c+E+e–; K–; father: group O, 
D+C+c+E+e+; K–; and baby: A, D+C+c+E+e+; K–. DATs 
performed on the infant’s RBCs with polyspecific AHG and 
monospecific anti-IgG were positive (2+ and 3+, respectively). 
Table 2. Determination of the specificity of maternal alloantibody
Panel C c D E e K k Kpa Fya Fyb M N S s P1 Lea Leb Lua Lub Jka Jkb Wra Dia Xga Peculiarities IAT ENZ*
I + + + + + 0 + + 0 0 + + + + + + 0 0 + 0 + + + + 1+ 2+
II + + + 0 + + + 0 0 + + + + 0 0 0 0 0 + + 0 0 0 0 1+ 2+
III + + + 0 + 0 + 0 + 0 0 + 0 + 0 0 + 0 + 0 + 0 0 0 1+ 2+
AUTO 0
1 + + + + + 0 + 0 0 0 + + + + + + 0 0 + 0 + 0 0 + 1+ 2+
2 + + + 0 + + + 0 0 + + + + 0 0 0 0 0 + + 0 0 0 0 1+ 1+
3 + + + 0 0 0 + 0 + 0 0 + 0 + 0 0 + 0 + 0 + + 0 0 0 0
4 + + + 0 + + + + 0 0 + + + + 0 0 0 + 0 + 0 0 0 0 1+ 2+
5 0 0 + 0 + 0 + 0 + 0 + 0 + + + 0 0 0 + 0 + 0 0 + 1+ 2+
6 + 0 + 0 + 0 + 0 + 0 + + 0 + 0 0 0 0 + + + 0 0 + 2+ 3+
7 0 + 0 + 0 0 + 0 + + + + + + 0 0 + 0 + 0 + 0 + 0 0 0
8 0 + 0 0 + 0 + 0 + 0 + + 0 + + + 0 0 + 0 + 0 0 0 1+ 2+
9 0 + 0 0 + 0 + 0 0 0 0 + 0 + + ? 0 + 0 + + 0 0 + Cw(+), Js(a+) 1+ 1+
10 0 + 0 0 + 0 + 0 0 0 + + + 0 0 + 0 0 + + + 0 0 0 1+ 2+
*Papain-treated red blood cells. Red font highlights reactivity with e+ and e– panel red blood cells.
IAT = indirect antiglobulin test; AUTO = autocontrol.
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The maternal plasma was positive by the IAT with antibody 
detection RBCs. Anti-e was identified, reacting by the IAT with 
untreated and papain-treated RBCs (Table 2). Since anti-C 
can be present with anti-e, anti-C exclusion was verified by 
confirming the results on panel cells 1, 3, 5, and 7 in repeat 
testing. Titer results were 512 and 1024 using untreated 
and papain-treated RBCs, respectively. These results were 
supported by the molecular testing that showed the absence 
of the corresponding primer amplification product for e in the 
mother but showed its presence in the father and the newborn. 
(Fig. 1) Based on the serologic and molecular testing and on the 
phenotype and population frequencies, the haplotypes for the 
mother, father, and newborn were predicted to be DcE/dcE, 
DCE/dce, and DcE/dce, respectively. The investigation was 
concluded as HDFN due to anti-e.
Discussion
HDFN due to antibodies in the Rh system (HDFN-Rh) is 
usually severe, particularly if due to anti-D, which historically 
has an incidence of 18 percent in the pregnancies of D– 
women. With the introduction of Rh immune globulin (RhIG) 
immunoprophylaxis, the incidence of HDFN due to anti-D 
dramatically decreased to ~1 percent. In Cuba, its incidence is 
<1 percent. The remaining cases of RhD-HDFN occur because 
of sensitization during pregnancy; no administration of RhIG 
after delivery of a D+ child, an abortion, or other immunizing 
event (poorly matched transfusions); and administration of an 
insufficient dose of RhIG to cover a large antigenic stimulus.4 
Maternal alloimmunization against other blood group antigens 
is very rare.5
While antibodies to C, c, E, and e have been implicated 
as a cause of HDFN, anti-e has been noted to be only weakly 
antigenic and not a significant cause of severe isoimmunization 
and hemolytic disease.6,7
The e antigen has a prevalence of 98 percent in the white 
and black populations and 96 percent in the Asian population. 
In Cuba, the prevalence of e is >98 percent.8 Because few 
individuals can produce alloanti-e, the occurrence of HDFN 
by immunization against this antigen alone is uncommon.9 
The literature contains several case reports.6,10,11 In 2012, 
Karagol et al.12 studied 106 HDFN cases in Turkey caused 
by antibodies against K, C, c, E, and e. HDFN due to anti-e 
was reported in 5 (4.7%) of the 106 cases.12 Our facility is the 
national reference laboratory for HDFN investigation; there 
are no cases of HDFN due to anti-e in our historical archives. 
This case constitutes the first report.
Despite the few reports, there are differences between the 
cases relative to the degree of severity and the presentation of 
the disease. For example, Hanzlick and Senhauser13 reported 
a subclinical HDFN due to anti-e in 1979. Our assessment 
Fig. 1 Amplification products corresponding to the Rh genotype of 
mother (A), father (B), and baby (C). The control of the amplification 
used, human growth hormone (HGH), is indicated with the arrow. 
The presence or absence of amplification for RhC (137 bp) and Rhe 
(158 bp) are indicated by the circled results of each tested sample. 
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of severity is based on the criteria of the Subcommittee on 
Hyperbilirubinemia of the American Academy of Pediatrics, 
which assigns a high risk of kernicterus in term neonates 
when total bilirubin levels are ≥137 µmol/L at 24 hours, ≥222 
µmol/L at 48 hours, and ≥290 µmol/L at 84 hours of life.14
The most clinically significant forms of HDFN are caused 
by maternal blood group alloantibodies of IgG1 and IgG3 
subclasses, which cause hemolysis more effectively than 
other IgG subclasses. IgG1 and IgG3 are transported across 
the placenta by the Fc receptor beginning in the second 
trimester. Once in the fetal circulation, the antibody binds to 
antigen-positive fetal RBCs that are then cleared by the fetal 
spleen. Free hemoglobin is metabolized into bilirubin that is 
conjugated by the maternal liver.15
At birth, the connection to the maternal circulation is 
severed, causing the risk of neonatal hyperbilirubinemia to 
increase significantly because of the immature development 
of the metabolic pathway to break down bilirubin in the 
neonatal liver. Although most jaundice in newborns is 
benign, management of hyperbilirubinemia is critical in the 
neonatal period because of the risk for bilirubin-induced 
encephalopathy.14 Affected infants may need phototherapy to 
oxidize unconjugated bilirubin to allow for urinary excretion. 
For neonates diagnosed with HDFN, close observation of 
bilirubin and hemoglobin levels is warranted to determine 
whether exchange transfusion is needed to remove bilirubin 
and maternal antibody and/or if transfusions are indicated 
to support oxygen-carrying capacity to the tissues. Admin-
istration of IVIG to the newborn has been used to reduce 
the need for exchange transfusions and phototherapy, but it 
does not affect the need for top-off transfusions. A Cochrane 
review by Rath et al.16 suggests that more study is needed to 
determine the best use of IVIG in this setting. When bilirubin 
reaches critical levels, exchange transfusion is indicated. Blood 
product selection is similar to that for intrauterine transfusions; 
however, because the infant’s whole blood is being removed, 
the RBC unit is usually mixed with a plasma unit to create 
reconstituted whole blood. After a two-volume exchange 
transfusion, ~90 percent of the RBCs have been replaced and 
50 percent of the bilirubin has been removed.14
The high prevalence of e in the Cuban population 
prevented the treatment of the high total bilirubin levels by 
exchange transfusion in accordance with current clinical 
practice guidelines.14 A total of 135 units of RBC concentrates 
were tested and only 1 unit (0.7%) was e–.
In contrast to RhD- and ABO-HDFN, no critical antibody 
titer levels were determined for the monitoring of HDFN due 
to other blood group antibodies. However, in our report, we 
found high levels of maternal anti-e similar to those induced 
in RhD-HDFN, which resulted in significant anemia and 
hyperbilirubinemia. In the obstetric history of the mother, 
there is no reference to the performance of the IAT for the 
detection of antibodies against fetal erythrocytes, which 
limited the ability to detect the disease during the fetal period. 
Maternal alloimmunization was likely triggered by prior blood 
transfusions or by fetomaternal hemorrhage in a previous 
pregnancy. Antigenic stimulation was reinforced during the 
current pregnancy and is likely the cause of the high antibody 
titers observed.
The RBC antibody titer, or concentration, helps with 
further stratification, although the relatively subjective nature 
of these assays should always be kept in mind.17 Traditionally, 
serial antibody titers are used to detect ongoing sensitization, 
with arbitrary thresholds of increasing antibody strength 
used to indicate ongoing and increasing immune stimulation, 
presumably due to the presence of the specific fetal RBC 
antigen. If there was a previously affected pregnancy, trending 
of the titer will not be a reliable measure of increasing 
sensitization. In addition, transfusion laboratories establish 
critical antibody titers at which the antibody concentration has 
reached a level that may lead to significant fetal anemia (titers 
of 16–32 are commonly used).18
Very few cases of HDFN due to anti-e are reported in the 
literature, and there are fewer cases in which other antibodies 
are also present.19 Because the mother also lacks C, HDFN could 
be produced by anti-C that was present but masked by the anti-e. 
This possibility was addressed by the repeat testing to exclude 
anti-C performed during antibody identification studies.
The major limitation in our interpretation lies in the inability 
to confirm that anti-e caused the HDFN by eluting the antibody 
from the RBCs of the neonate. Umbilical blood samples were 
not collected for this study because the clinical manifestations 
in the newborn did not appear until 8 hours after birth, and 
the peripheral blood sample from the newborn sent to our 
laboratory was not large enough to perform the elution.
Although molecular studies are used to predict the risk 
of HDFN in the fetal period, this is not a test of choice for 
the postnatal diagnosis of HDFN. Given the infrequency of 
e within the Cuban population, we used molecular testing 
to corroborate the mother’s RBCs were e– and to help us in 
making the diagnosis.
Currently, more than 100 RBC antigen/antibody pairs are 
recognized as potentially causing HDFN when incompatibility 
between mother’s antibody and fetal RBCs exists. In most 
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countries that have prenatal diagnosis programs for HDFN, 
only those cases in which the mother’s RBCs type as D– are 
monitored for maternal antibody formation. This finding means 
that HDFN caused by non-D blood group incompatibilities is 
not diagnosed in time or is overlooked, so these programs must 
include maternal antibody detection testing in all pregnancies.
At the same time, other considerations in the newborn need 
to be investigated when acute severe jaundice presents within 
the first 2 days and when there is an acute severe hemolysis as 
in this index newborn. Phototherapy and exchange transfusion 
remain the standard treatment modalities in newborns with 
severe jaundice. Considering similar pathophysiology to D 
immunization, however, early IVIG may prevent acute and 
severe onset of jaundice.
Since HDFN was first recognized, it has been the subject of 
concern for obstetricians, neonatologists, and hemotherapists. 
Currently, there is an arsenal of diagnostic and therapeutic 
methods that allow prevention, early diagnosis, and effective 
treatment; therefore, whenever the possibility of this disease is 
suspected, it is necessary to determine the antibody involved 
and its clinical importance to help reduce the incidence of 
morbidity and mortality.
Acknowledgments
The authors would like to acknowledge Mariela Forrellat 
Barrios, MS, for her assistance in the review of this report and 
Ileana Martínez Pitaluga for providing useful information and 
recommendations.
References
 1. deHaas M, Thurik FF, Koelewijn JM, van der Schoot CE. 
Haemolytic disease of the fetus and newborn. Vox Sang 
2015;109:99–113.
 2. Fung MK, Eder AF, Spitalnik S, Westhoff CM, Eds. Technical 
manual. 19th ed. Bethesda, MD: AABB, 2017.
 3. Gassner C, Schmarda A, Kilga-Nogler S, et al. RHD/CE typing 
by polymerase chain reaction using sequence-specific primers. 
Transfusion 1997;37:1020–6.
 4. Alfonso ME, Muñiz E, Bencomo AA, et al. Aloinmunización 
contra células sanguíneas en el primer trimestre del embarazo. 
Rev Cubana Hematol Immunol Hemoter. 2006 May–August; 
22. Available from http://scielo.sld.cu/scielo.php?script=sci_
arttext&pid=S0864-02892006000200006&lng=es. Accessed 
16 March 2021.
 5. Alfonso ME, Muñíz E, Bencomo AA, et al. Aloanticuerpos 
contra células sanguíneas en embarazadas nulíparas antes 
y después de abortos provocados. Rev Cubana Hematol 
Inmunol Hemoter. 2008 May–August; 24. Available from 
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-
02892008000200007&lng=es. Accessed 16 March 2021.
 6. McAdams RM, Dotzler SA, Winter LW, Kerecman JD. Severe 
hemolytic disease of the newborn from anti-e. J Perinatol 
2008;28:230–32.
 7. Eder AF. Update on HDFN: new information on long-standing 
controversies. Immunohematology 2006;22:188–95.
 8. Bencomo AA, Alfonso Y, Alfonso ME, González R, Martínez 
M. Frecuencia de los grupos sanguíneos ABO y Rh endonantes 
de sangrecubanos. Rev Argent Transfus 1997;23:20–1.
 9. Daniels G, Ed. Rh and RHAG blood group system. In: Human 
bloodgroups. 3rd ed. Oxford: Blackwell Scientific, 2013: 
182–258.
 10. Chapman J, Waters AH. Haemolytic disease of the newborn 
due to Rhesus anti-e antibody. Vox Sang 1981;41:45–7.
 11. Ali HA, Zohud OS. Hemolytic disease of the newborn due to 
anti e. J Clin Neonatol 2002;9:146–8.
 12. Karagol BS, Zenciroglu A, Okumus N, Karadag N, Dursun 
A, Hakan N. Hemolytic disease of the newborn caused by 
irregular blood subgroup (Kell, C, c, E, and e) incompatibilities: 
report of 106 cases at a tertiary-care centre. Am J Perinatol 
2012;29:449–54.
 13. Hanzlick RL, Senhauser DA. Subclinical hemolytic disease of 
the newborn due to anti-e. Am J Clin Pathol 1979;72:76–9.
 14. American Academy of Pediatrics, Subcommittee on 
Hyperbilirubinemia. Management of hyperbilirubinemia in 
the newborn infant 35 or more weeks of gestation. Pediatrics 
2004;114:297–316.
 15. Firan M, Bawdon R, Radu C, et al. The MHC class I-related 
receptor, FcRn, plays an essential role in the maternofetal 
transfer of gamma-globulin in humans. Int Immunol 
2001;13:993–1002.
 16. Rath ME, Smits-Wintjens VE, Walther FJ, Lopriore E. 
Hematological morbidity and management in neonates with 
hemolytic disease due to red cell alloimmunization. Early Hum 
Dev 2011;87:583–8.
 17. AuBuchon JP, de Wildt-Eggen J, Dumont LJ. Reducing the 
variation in performance of antibody titrations. Arch Pathol 
Lab Med 2008;132:1194–201
 18. Delaney M, Matthews DC. Hemolytic disease of the fetus 
and newborn: managing the mother, fetus, and newborn. 
Hematology Am Soc Hematol Educ Program 2015;2015: 
146–51.
 19. Sharma D, Dannapuneni N, Murki S, Pratap T. Combined anti 
e and anti C Rh isoimmunisation and severe hyperbilirubine-
mia. Indian J Pediatr 2015;82:570.
Gilberto Soler-Noda, MS (corresponding author), Auxiliary Professor, 
Auxiliary Investigator, Laboratory of Immunohematology, National 
Institute of Hematology and Immunology, La Habana, Habana, 
Cuba, CP 10400, gsolern@infomed.sld.cu; Yisenia Romero-Díaz, BS, 
Aggregate Investigator, Laboratory of Immunohematology, National 
Institute of Hematology and Immunology, La Habana, Habana, 
Cuba; Lisette Orbeal-Aldama, Specialist of Immunohematology, 
Laboratory of Immunohematology, National Institute of Hematology 
and Immunology, La Habana, Habana, Cuba; and Suharmi 
Aquino-Rojas, BS, Specialist in Medicine Transfusion, Laboratory 
of Immunohematology, National Institute of Hematology and 
Immunology, La Habana, Habana, Cuba.
